title: Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation.
abstract: We report the results of 84 patients with ALL after related (n = 46) or unrelated (n = 38) allogeneic SCT. Mean recipient age was 23 years (range: 1-60) and median follow-up was 18 months (range: 1-133). Forty-three patients were transplanted in CR1; 25 in CR2 or CR3; four were primary refractory; four in PR; eight in relapse. The conditioning regimen consisted of TBI/VP16/CY (n = 76), TBI/VP16 (n = 2), TBI/CY (n = 2), Bu/VP16/CY (n = 4). The OS at 3 years was 45% (44% unrelated, 46% related). Univariate analysis showed a significantly better OS for patients <18 years (P=0.03), mismatched sex-combination (P = 0.03), both with a stronger effect on increasing OS after unrelated SCT. Factors decreasing TRM were patient age <18 years (P = 0.004), patient CMV-seronegativity (P = 0.014), female recipient (P = 0.04). There was no significant difference in TRM and the relapse rate was similar in both donor type groups. Multivariate analysis showed that factors for increased OS which remained significant were mismatched sex-combination (RR: 0.70,95% CI: 0.51-0.93, P = 0.015), patient age < 18 years (RR: 0.66, 95% CI: 0.47-0.93, P = 0.016). A decreased TRM was found for female patients (RR: 0.56, 95% CI: 0.33-0.98, P=0.042), negative CMV status of the patient (RR: 0.57, 95% CI: 0.36-0.90, P = 0.015). Unrelated stem cell transplantation for high-risk ALL patients with no HLA-compatible family donor is justifiable.
authors.affiliation: Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Dahlke
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: T
authors.initials: T
authors.lastname: Zabelina
authors.forename: F
authors.initials: F
authors.lastname: Ayuk
authors.forename: N
authors.initials: N
authors.lastname: Fehse
authors.forename: C
authors.initials: C
authors.lastname: Wolschke
authors.forename: O
authors.initials: O
authors.lastname: Waschke
authors.forename: H
authors.initials: H
authors.lastname: Schieder
authors.forename: H
authors.initials: H
authors.lastname: Renges
authors.forename: W
authors.initials: W
authors.lastname: Krüger
authors.forename: A
authors.initials: A
authors.lastname: Kruell
authors.forename: A
authors.initials: A
authors.lastname: Hinke
authors.forename: R
authors.initials: R
authors.lastname: Erttmann
authors.forename: H
authors.initials: H
authors.lastname: Kabisch
authors.forename: A R
authors.initials: AR
authors.lastname: Zander
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000401:mortality; D018572:Disease-Free Survival; D046148:Donor Selection / Q000379:methods; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000401:mortality* / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous